青县找算命好的大师祁阳哪有算命的,黄平哪里算卦算的好,龙游哪里有算命的师傅,沾化哪里有看的准的看相,斗六市算命大师,景洪市内哪里算命准,上高哪里有算命的师傅

SAN FRANCISCO, June 28 (Xinhua) -- Google Android chief Andy Rubin said on Tuesday that the activations of Android-powered devices are growing at a rate of 4.4 percent on a weekly basis, with over 500,000 devices activated each day worldwide."There are now over 500,000 Android devices activated every day, and it's growing at 4.4 percent w/w," tweeted Rubin, Google's Senior Vice President of Mobile who oversees the development of Android, the open-source operating system for smartphones.Last month, Google said at its annual developer conference Google I/O that 400,000 Android devices were being activated each day, compared with 300,000 daily activations in December and 100, 000 in May 2010.More research data have shown Android system's soaring market share and popularity. Earlier this month, Internet market research company ComScore reported that Android remained the No. 1 smartphone operating system in the United States over the three months ending in April. The system captured 36.4 percent of U.S. smartphone subscribers, while Apple's iOS system for iPhone had 26 percent of all smartphone users.In April, market research company Gartner said in a forecast that the Android operating system will own 49.2 percent of the global smartphone market and Apple's iOS will have an 18.9-percent share in the second place.

WASHINGTON, Sept. 14 (Xinhua) -- Controlling diabetes may someday involve mining stem cells from the lining of the uterus, Yale School of Medicine researchers report in a new study published Wednesday in the journal Molecular Therapy. The team treated diabetes in mice by converting cells from the uterine lining into insulin-producing cells.The endometrium or uterine lining, is a source of adult stem cells. These cells generate uterine tissue each month as part of the menstrual cycle. Like other stem cells, however, they can divide to form other kinds of cells.Led by Yale Professor Hugh Taylor, the researchers bathed endometrial stem cells in cultures containing special nutrients and growth factors. Responding to these substances, the endometrial stem cells adopted the characteristics of beta cells in the pancreas that produce insulin. Over the course of a three- week incubation process, the endometrial stem cells took on the shape of beta cells and began to make proteins typically made by beta cells. Some of these cells also produced insulin.After a meal, the body breaks food down into components like the sugar glucose, which then circulates in the blood. In response, beta cells release insulin, which allows the body's cells to take in the circulating glucose. In this study, Taylor and his team exposed the mature stem cells to glucose and found that, like typical beta cells, the cultured cells responded by producing insulin. The team then injected diabetic mice with the mature, insulin-making stem cells. The mice had few working beta cells and very high levels of blood glucose.Mice that did not receive the stem cell therapy continued having high blood sugar levels, developed cataracts and were lethargic. In contrast, mice that received the cell therapy were active and did not develop cataracts, but the animals' blood sugar levels remained higher than normal.The Yale team's findings suggest that endometrial stem cells could be used to develop insulin-producing islet cells, which are found in the pancreas. These islet cells could then be used to advance the study of islet cell transplantation to treat people with diabetes.Taylor said in a statement that the next step in the research will be to verify how long this treatment remains effective.

SAN FRANCISCO, Aug. 15 (Xinhua) -- Facebook and Yahoo on Monday started to test "six degrees of separation," an iconic social experiment in the 1960s that showed everyone is on average approximately six steps away from any other person on earth.The current Facebook-Yahoo "small world" experiment, based on more than 750 million active Facebook users, is expected to determine the social path length between two strangers.Anyone with a Facebook account can participate by going to smallworld.sandbox.yahoo.com and will be assigned a "target person. " The participant will be asked to select one of his or her Facebook friends, whom will be forwarded a message and then pass the message from friend to friend so that the participant will get a message to the "target person" in as few steps as possible.The study is intended as academic social research and will be published in peer-reviews scientific journal, Duncan Watts, Yahoo' s principal research scientist who is leading the experiment, told San Jose Mercury News.In the 1960s, American social psychologist Stanley Milgram and other researchers conducted several experiments to examine the average path length for social networks of people in the United States, suggesting that human society is a small world type network by around 5.5 people steps or about six people on average.It is now currently accepted that there were potential flaws in the so-called "small world experiment" because the conclusions were based on relatively small number of research samples.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, Aug. 23 (Xinhua) -- The amount of malware targeted at devices based on Google's Android platform surged 76 percent in the second quarter over the previous three months in 2011, making it the most attacked mobile operating system, computer security firm McAfee said on Tuesday.A new McAfee study found that in the second quarter, Android- based malware surpassed Nokia's Symbian as the most popular target for mobile malware developers.While Symbian and Java ME, a platform designed for mobile devices and other embedded systems, remain the most targeted to date, the rapid rise in Android malware indicates that the platform could become an increasing target for cyber criminals McAfee said.Models pose with the new Samsung Galaxy S Android smartphone during its launch ceremony at the headquarters of Samsung Electronics in Seoul in this June 8, 2010 file photograph.It warned that the attacks on Android platform could affect everything from calendar apps, to text messages, and even a fake Angry Birds updates.According to the study, malware on mobile platforms is increasing steadily, often mimicking the same code as personal computer-based threats, as vast amount of personal and business data are now found on user's smartphones and other mobile devices."This year we've seen record-breaking numbers of malware, especially on mobile devices, where the uptick is in direct correlation to popularity," Vincent Weafer, senior vice president of McAfee Labs, said in a statement."Overall attacks are becoming more stealth and more sophisticated, suggesting that we could see attacks that remain unnoticed for longer periods of time," he noted.